EUVIMEDEUVIMED entdecken
Open Access

Regional trends and disparities in newer GLP1 receptor agonist initiation among real‐world adult patients eligible for obesity treatment

Rotana M Radwan iD, Yao An Lee, Pareeta Kotecha iD, Davene R Wright, Inmaculada Hernandez, Ronald Ramon, William T Donahoo, Yong Chen, John M Allen, Jiang Bian, Jingchuan Guo iD

Diabetes, Obesity and Metabolism · 2025-06 · 27 (6) · 3113-3123

DOI: 10.1111/dom.16318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 04.03.2025. Verfasst von Rotana M Radwan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Healthcare Disparities, Anti-Obesity Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, the National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To characterize trends in the initiation of newer anti‐obesity medications (AOMs) and determine factors associated with their use among obese/overweight populations. Materials and Methods This study utilized electronic health record data from OneFlorida+ (2015–2024). Adults eligible for AOMs were included, defined as having a body mass index (BMI) ≥30 kg/m 2 or a BMI of 27–29.9 kg/m 2 with at least one obesity‐related comorbidity. The primary outcome was the initiation of newer AOMs, specifically glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) including liraglutide, semaglutide and tirzepatide. Trends across years were examined, and a multivariable logistic regression identified sociodemographic, clinical and healthcare utilization factors associated with AOM initiation.

Results

Of 319,949 adults, 1.8% initiated newer AOMs . Semaglutide accounted for 77.9% of initiations, tirzepatide 19.7% and liraglutide 17.8%. Initiation trends showed liraglutide uptake peaked at 5% in 2018 but declined afterward, while semaglutide and tirzepatide uptake increased exponentially since 2022. Odds of initiation were lower for Black ( aOR [95% CI ]: 0.87 [0.80–0.94]) and Hispanic (0.84 [0.78–0.91]) groups versus Whites, and for Medicaid (0.69 [0.63–0.76]) and uninsured (0.81 [0.74–0.87]) patients versus privately insured. Higher odds were associated with being female, middle‐aged, having more outpatient visits and visiting endocrinologists.

Conclusions

The initiation of newer AOMs among overweight and obese populations remains low, but uptake has increased exponentially since 2022. Our findings reveal significant disparities in obesity care, highlighting the importance of addressing inequities in AOM access to improve obesity outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityGlucagon-Like Peptide-1 Receptor AgonistsHealthcare DisparitiesAnti-Obesity AgentsHumansFemaleMaleMiddle AgedAdultLiraglutideGlucagon-Like PeptidesUnited StatesBody Mass IndexGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP1 receptor agonistsanti‐obesity medicationshealth disparitiesobesity

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsAnti-Obesity AgentsLiraglutideGlucagon-Like PeptidesGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, Florida, USA.
  • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Division of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, La Jolla, California, USA.
  • University of Florida College of Pharmacy, Gainesville, Florida, USA.
  • Division of Endocrinology, Diabetes and Metabolism, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Rotana M Radwan, Pareeta Kotecha, Jingchuan Guo

Förderung

  • NIDDK NIH HHS
  • the National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Zitieren

APA

Radwan, R. M., Lee, Y. A., Kotecha, P., Wright, D. R., Hernandez, I., Ramon, R., Donahoo, W. T., Chen, Y., Allen, J. M., Bian, J., & Guo, J. (2025). Regional trends and disparities in newer GLP1 receptor agonist initiation among real‐world adult patients eligible for obesity treatment. Diabetes, Obesity and Metabolism, 27(6), 3113-3123. https://doi.org/10.1111/dom.16318

Vancouver

Radwan RM, Lee YA, Kotecha P, Wright DR, Hernandez I, Ramon R, et al. Regional trends and disparities in newer GLP1 receptor agonist initiation among real‐world adult patients eligible for obesity treatment. Diabetes, Obesity and Metabolism. 2025;27(6):3113-3123. doi:10.1111/dom.16318

BibTeX
@article{Radwan2025,
  author = {Radwan, Rotana M and Lee, Yao An and Kotecha, Pareeta and Wright, Davene R and Hernandez, Inmaculada and Ramon, Ronald and Donahoo, William T and Chen, Yong and Allen, John M and Bian, Jiang and Guo, Jingchuan},
  title = {Regional trends and disparities in newer GLP1 receptor agonist initiation among real‐world adult patients eligible for obesity treatment},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {6},
  pages = {3113--3123},
  doi = {10.1111/dom.16318}
}
Kostenlos starten →